Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	The Angels Initiative Stroke prevention

Bladder Cancer

Free Subscription 23.01.2023 1 Am J Surg Pathol 1 Analyst 1 Ann Transl Med 1 Appl Biochem Biotechnol 2 Asia Pac J Clin Oncol 1 Biomed Rep 1 Bioorg Med Chem 1 Cancer Control 1 Cell Rep Med 1 Clin Cancer Res 1 Commun Med (Lond) 1 Cost Eff Resour Alloc 1 Heliyon 1 Indian J Pathol Microbiol 1 Int J Urol 2 J Cancer Res Ther 2 J Clin Oncol 1 J Pathol 1 JAMA 1 Lasers Med Sci 1 Med Oncol 1 Mol Med 1 Nan Fang Yi Ke Da Xue Xue Bao 1 Nat Rev Urol 1 NPJ Precis Oncol 1 Pharmacol Res 1 Qual Life Res 1 Res Rep Urol 1 Scand J Urol 1 Sci Rep 1 Tomography 2 Urol Int 2 Urol Oncol 1 Urologia 1 World J Oncol

Retrieve available abstracts of this week’s articles: HTML format

Single Articles

Am J Surg Pathol

1. HOGAN K, McKenney JK, Cox RM, Nguyen JK, et al
   Myxoid Pseudotumor Involving the Renal Sinus: Clinicopathologic Study of 33 Cases Supporting a Distinct Benign Non-neoplastic Lesion.
   Am J Surg Pathol. 2023;47:218-223.
   PubMed         Abstract available
   
   

   
   Analyst

2. KUJDOWICZ M, Perez-Guaita D, Chlosta P, Okon K, et al
   Evaluation of grade and invasiveness of bladder urothelial carcinoma using infrared imaging and machine learning.
   Analyst. 2022 Dec 16. doi: 10.1039/d2an01583.
   PubMed         Abstract available
   
   

   
   Ann Transl Med

3. WU J, Wang X, Xu H, Tian J, et al
   Bioinformatics analysis of the correlation between m6A RNA methylation regulators and the immune infiltration and prognosis of bladder cancer.
   Ann Transl Med. 2022;10:1386.
   PubMed         Abstract available
   
   

   
   Appl Biochem Biotechnol

4. WU X, Xu Q, Li T, Wei Y, et al
   Bladder Cancer Progression Is Suppressed Through the Heart and Neural Crest Derivatives Expressed 2-Antisense RNA 1/microRNA-93-5p/Defective in Cullin Neddylation 1 Domain Containing 3 Axis.
   Appl Biochem Biotechnol. 2023 Jan 19. doi: 10.1007/s12010-022-04295.
   PubMed         Abstract available
   
   

   
   Asia Pac J Clin Oncol

5. WANG S, Yu Z, Du P, Cao Y, et al
   Combination of hyperthermia and intravesical chemotherapy for the treatment of pT1 stage bladder cancer: A retrospectively clinical study.
   Asia Pac J Clin Oncol. 2023 Jan 19. doi: 10.1111/ajco.13931.
   PubMed         Abstract available
   
   
6. SHIMURA S, Matsumoto K, Ikeda M, Moroo S, et al
   A multi-institutional retrospective study of open versus laparoscopic nephroureterectomy focused on the intravesical recurrence.
   Asia Pac J Clin Oncol. 2023;19:71-78.
   PubMed         Abstract available
   
   

   
   Biomed Rep

7. LIU W, Xu Y, Bai S, Liao L, et al
   Bioinformatics analysis of key biomarkers for bladder cancer.
   Biomed Rep. 2022;18:14.
   PubMed         Abstract available
   
   

   
   Bioorg Med Chem

8. ORSI DL, Ferrara SJ, Siegel S, Friberg A, et al
   Discovery and characterization of orally bioavailable 4-chloro-6-fluoroisophthalamides as covalent PPARG inverse-agonists.
   Bioorg Med Chem. 2022;78:117130.
   PubMed         Abstract available
   
   

   
   Cancer Control

9. LIN W, Pan X, Zhang C, Ye B, et al
   Impact of Age at Diagnosis of Bladder Cancer on Survival: A Surveillance, Epidemiology, and End Results-Based Study 2004-2015.
   Cancer Control. 2023;30:10732748231152322.
   PubMed         Abstract available
   
   

   
   Cell Rep Med

10. WU J, Jin S, Gu C, Wei Y, et al
    Inherited mutations in Chinese patients with upper tract urothelial carcinoma.
    Cell Rep Med. 2023;4:100883.
    PubMed         Abstract available
    
    

    
    Clin Cancer Res

11. CHOPRA S, Trepka K, Sakhamuri S, Carretero-Gonzalez A, et al
    Theranostic targeting of CUB domain containing protein 1 (CDCP1) in multiple subtypes of bladder cancer.
    Clin Cancer Res. 2023 Jan 17:CCR-22-1973. doi: 10.1158/1078-0432.CCR-22-1973.
    PubMed         Abstract available
    
    

    
    Commun Med (Lond)

12. CARVALHO LB, Capelo JL, Lodeiro C, Dhir R, et al
    Pathway-guided monitoring of the disease course in bladder cancer with longitudinal urine proteomics.
    Commun Med (Lond). 2023;3:8.
    PubMed         Abstract available
    
    

    
    Cost Eff Resour Alloc

13. RAADABADI M, Daroudi R, Zendehdel K, Haghdoost AA, et al
    Direct and indirect medical costs of bladder cancer in Iran.
    Cost Eff Resour Alloc. 2023;21:5.
    PubMed         Abstract available
    
    

    
    Heliyon

14. VILLANUEVA H, Wells GA, Miller MT, Villanueva M, et al
    Characterizing treatment resistance in muscle invasive bladder cancer using the chicken egg chorioallantoic membrane patient-derived xenograft model.
    Heliyon. 2022;8:e12570.
    PubMed         Abstract available
    
    

    
    Indian J Pathol Microbiol

15. YADAV K, Agarwal P, Kumar M, Gupta S, et al
    Immunohistochemical appraisal of epithelial mesenchymal transition type III in gall bladder cancer.
    Indian J Pathol Microbiol. 2023;66:44-53.
    PubMed         Abstract available
    
    

    
    Int J Urol

16. NASELLI A, Pirola GM
    Editorial Comment to Significance of dorsal bladder neck involvement in predicting the progression of non-muscle-invasive bladder cancer.
    Int J Urol. 2023 Jan 18. doi: 10.1111/iju.15150.
    PubMed        
    
    

    
    J Cancer Res Ther

17. GU J, He Z, Chen Z, Wu H, et al
    Efficacy and safety of 2-micron laser versus conventional trans-urethral resection of bladder tumor for non-muscle-invasive bladder tumor: A systematic review and meta-analysis.
    J Cancer Res Ther. 2022;18:1894-1902.
    PubMed         Abstract available
    
    
18. JI J, Yao Y, Guan F, Sun L, et al
    Efficacy and adverse reactions of intra-arterial chemotherapy in patients with bladder cancer: A systematic review and meta-analysis.
    J Cancer Res Ther. 2022;18:1884-1893.
    PubMed         Abstract available
    
    

    
    J Clin Oncol

19. STERNBERG CN, Petrylak DP, Bellmunt J, Nishiyama H, et al
    FORT-1: Phase II/III Study of Rogaratinib Versus Chemotherapy in Patients With Locally Advanced or Metastatic Urothelial Carcinoma Selected Based on FGFR1/3 mRNA Expression.
    J Clin Oncol. 2023;41:629-639.
    PubMed         Abstract available
    
    
20. SADEGHI S, Quinn D, Dorff T, Pal S, et al
    EphrinB2 Inhibition and Pembrolizumab in Metastatic Urothelial Carcinoma.
    J Clin Oncol. 2023;41:640-650.
    PubMed         Abstract available
    
    

    
    J Pathol

21. PETTITT GA, Hurst CD, Khan Z, McPherson HR, et al
    Development of resistance to FGFR inhibition in urothelial carcinoma via multiple pathways in vitro.
    J Pathol. 2023;259:220-232.
    PubMed         Abstract available
    
    

    
    JAMA

22. RUBIN R
    New Gene Therapy for Certain Bladder Cancers.
    JAMA. 2023;329:201.
    PubMed        
    
    

    
    Lasers Med Sci

23. ZHANG W, Zhou B, Deng J, Han G, et al
    Retrospective analysis of 1470-/980-nm dual-wavelength laser en bloc resection versus transurethral resection of bladder tumor for primary non-muscle-invasive bladder cancer.
    Lasers Med Sci. 2023;38:44.
    PubMed         Abstract available
    
    

    
    Med Oncol

24. SELIM MS, Kassem AB, El-Bassiouny NA, Salahuddin A, et al
    Polymorphic renal transporters and cisplatin's toxicity in urinary bladder cancer patients: current perspectives and future directions.
    Med Oncol. 2023;40:80.
    PubMed         Abstract available
    
    

    
    Mol Med

25. LUO M, Zhang Y, Xu Z, Lv S, et al
    Experimental analysis of bladder cancer-associated mutations in EP300 identifies EP300-R1627W as a driver mutation.
    Mol Med. 2023;29:7.
    PubMed         Abstract available
    
    

    
    Nan Fang Yi Ke Da Xue Xue Bao

26. FU X, Yu G, Guo Y
    [Expression pattern of the histone lysine demethylase family and its potential role in bladder cancer: a multi-omics analysis].
    Nan Fang Yi Ke Da Xue Xue Bao. 2022;42:1822-1831.
    PubMed         Abstract available
    
    

    
    Nat Rev Urol

27. GROBET-JEANDIN E, Pinar U, Parra J, Roupret M, et al
    Health-related quality of life after curative treatment for muscle-invasive bladder cancer.
    Nat Rev Urol. 2023 Jan 18. doi: 10.1038/s41585-022-00693.
    PubMed         Abstract available
    
    

    
    NPJ Precis Oncol

28. CHAUHAN PS, Shiang A, Alahi I, Sundby RT, et al
    Urine cell-free DNA multi-omics to detect MRD and predict survival in bladder cancer patients.
    NPJ Precis Oncol. 2023;7:6.
    PubMed         Abstract available
    
    

    
    Pharmacol Res

29. WU Q, Chen P, Li J, Lin Z, et al
    Inhibition of bladder cancer growth with homoharringtonine by inactivating integrin alpha5/beta1-FAK/Src axis: A novel strategy for drug application.
    Pharmacol Res. 2023;188:106654.
    PubMed         Abstract available
    
    

    
    Qual Life Res

30. RAMMANT E, Fox L, Beyer K, Aaronson NK, et al
    The current use of the EORTC QLQ-NMIBC24 and QLQ-BLM30 questionnaires for the assessment of health-related quality of life in bladder cancer patients: a systematic review.
    Qual Life Res. 2023 Jan 17. doi: 10.1007/s11136-022-03335.
    PubMed         Abstract available
    
    

    
    Res Rep Urol

31. NAGATA M, Ishizaka K, Asano T
    CD169(+) Macrophages Residing in the Draining Lymph Nodes and Infiltrating the Tumor Play Opposite Roles in the Pathogenesis of Bladder Cancer.
    Res Rep Urol. 2023;15:1-7.
    PubMed         Abstract available
    
    

    
    Scand J Urol

32. SECHER MS, Hyldgaard J, Jensen JB
    The association between gender, stage and prognosis in bladder cancer patients undergoing radical cystectomy.
    Scand J Urol. 2023 Jan 16:1-5. doi: 10.1080/21681805.2023.2166103.
    PubMed         Abstract available
    
    

    
    Sci Rep

33. BAXTER L, Gordon NS, Ott S, Wang J, et al
    Properties of non-coding mutation hotspots as urinary biomarkers for bladder cancer detection.
    Sci Rep. 2023;13:1060.
    PubMed         Abstract available
    
    

    
    Tomography

34. WANG Y, Zhang W, Xiao W, Chen S, et al
    Feasibility of Early Evaluation for the Recurrence of Bladder Cancer after Trans-Urethral Resection: A Comparison between Magnetic Resonance Imaging and Multidetector Computed Tomography.
    Tomography. 2022;9:25-35.
    PubMed         Abstract available
    
    

    
    Urol Int

35. FITOUSSI O, Roche JB, Riviere J, Wallerand H, et al
    Accuracy of FDG-PET/CT for Response Evaluation of Muscle-Invasive Bladder Cancer following Neoadjuvant or Induction Chemotherapy.
    Urol Int. 2023 Jan 19:1-7. doi: 10.1159/000528524.
    PubMed         Abstract available
    
    
36. TACHIBANA T, Ikeda M, Shimura S, Amano N, et al
    Efficacy of Intravesical Instillation Therapy with Low-Dose Tokyo-172 Bacillus Calmette-Guerin to Prevent Recurrence of Non-Muscle-Invasive Bladder Cancer and Treat Carcinoma in situ: A Multi-Institutional Retrospective Study.
    Urol Int. 2023 Jan 16:1-9. doi: 10.1159/000527718.
    PubMed         Abstract available
    
    

    
    Urol Oncol

37. SHEFER HK, Masarwe I, Bejar J, Naamnih LH, et al
    Performance of CellDetect for detection of bladder cancer: Comparison with urine cytology and UroVysion.
    Urol Oncol. 2023 Jan 13:S1078-1439(22)00497.
    PubMed         Abstract available
    
    
38. GOEBELL PJ, Kamat AM, Black PC, Dyrskjot L, et al
    Editorial: Cutting edge basic and clinical bladder cancer research - the IBCN updates.
    Urol Oncol. 2023 Jan 12:S1078-1439(22)00498.
    PubMed        
    
    

    
    Urologia

39. YUKSEL O, Tosun C, Gumrukcu G, Tokuc E, et al
    What is the role of CellDetect((R)) in detecting and monitoring bladder cancer?
    Urologia. 2023 Jan 20:3915603221150036. doi: 10.1177/03915603221150036.
    PubMed         Abstract available
    
    

    
    World J Oncol

40. WARLI SM, Prapiska FF, Siregar DIS, Wijaya WS, et al
    Association Between Interleukin-6 Levels and Lymph Node Metastasis in Bladder Cancer Patients.
    World J Oncol. 2022;13:365-369.
    PubMed         Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Bladder Cancer is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: